Leveraging “omics” for novel microbiome drug concepts
Posted: 29 October 2024 | Drug Target Review | No comments yet
Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.
In this episode, titled ‘Leveraging “omics” for novel microbiome drug concepts‘, we will discuss how can we leverage microbiomics to translate gut microbiome findings into new therapeutic options. Our speakers also share insights about what the future holds in this field.
This conversation features Johannes B. Woehrstein, CTO and co-founder of mbiomics, and Christopher Weidenmaier, CSO of mbiomics.
Key discussion points:
- What are the specific challenges the biotech industry needs to address to unlock the full potential of microbiome-based therapies?
- How can we apply “omics” approaches to understand pharmacokinetics and pharmacodynamics?
- Beyond LBP microbiome-based therapies, how can “omics” help to leverage the microbiome?
This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
About our speakers
Johannes B. Woehrstein, PhD, Chief Technology Officer and co-founder of mbiomics
Johannes B. Woehrstein, PhD, is co-founder and Chief Technology Officer of mbiomics. Drawing on 15 years of entrepreneurial experience, he invented multiple technologies that led to the launch of several biotech companies, including Ultivue and DEOXY.
Previously, he held positions as a principal investigator at the Faculty of Physics at Ludwig-Maximilians-Universität in Munich, Germany, and as a research scientist at the Wyss Institute at Harvard University. Jo holds a PhD in Physics from the Ludwig-Maximilians-Universität in Munich, Germany.
Christopher Weidenmaier, PhD, Chief Scientific Officer of mbiomics
Christopher Weidenmaier, PhD, is Chief Scientific Officer at mbiomics. He is a microbiologist and immunologist with nearly 20 years of experience in the microbiome and infectious diseases fields spanning from drug discovery to clinical development of therapeutic candidates across several indications.
Previously, Christopher held the position ofDirector of Research and Head of Host Cell Biology/Immunology at Finch Therapeutics.
Before that, he held positions as a principal investigator at the University of Tuebingen, Germany, and a prior postdoc position at Harvard Medical School in Boston. Christopher holds a PhD in Microbiology from the University of Tuebingen, Germany.
Related topics
Microbiome, Pharmacology, Therapeutics
Related organisations
mbiomics
